Major U.S. stock benchmarks closed higher on Monday, with the Dow Jones Industrial Average edging up 0.04% to 50,135.87, the S&P 500 rising 0.47% to 6,964.82, and the Nasdaq climbing 0.9% to 23,238.67.These are the top stocks that gained the attention of retail traders and investors through the day.Kyndryl Holdings, Inc. (NYSE:KD)Kyndryl Holdings stock tumbled 54.92% to close at $10.59, trading between an intraday high of $11.43 and a low of $10.10, with the stock sitting at its 52-week trough of $10.10 ver ...

Group 1 - Oil prices experienced a decline during the morning Asian session, attributed to potential position adjustments in the market [1] - Despite the drop, oil prices may find support due to escalating tensions between the U.S. and Iran, which could impact supply dynamics [1]

Key Takeaways Cloud computing remains a dominant investment theme, particularly so during the AI era. For those seeking exposure, Zacks Thematic Screens can lend a hand. Zacks Thematic Screens lets you dive into 30 dynamic investment themes shaping the future. Whether you're interested in cutting-edge technology, renewable energy, or healthcare innovations, our themes help you invest in ideas that matter to you..Let’s take a closer look at the ‘Cloud Computing’ theme and analyze a stock within, namely Micro ...

Core Viewpoint - Iveda announced a public offering of 5,714,286 shares of common stock and series X warrants, priced at $0.35 per share, aiming to raise approximately $2.0 million for general corporate purposes [1][3]. Group 1: Offering Details - The public offering includes 5,714,286 shares of common stock or pre-funded warrants and series X warrants to purchase up to 11,428,572 shares [1]. - The series X warrants will have an exercise price of $0.35 per share, exercisable immediately upon issuance, and will expire two years from the date of issuance [1]. - The closing of the offering is expected on or about February 11, 2026, subject to customary closing conditions [1]. Group 2: Financial Proceeds and Use - The gross proceeds from the offering are expected to be approximately $2.0 million before deducting fees and expenses [3]. - The net proceeds will be used for general corporate purposes, which may include research and development, repayment of existing debt, working capital, capital expenditures, acquisitions, joint ventures, and stock repurchase programs [3]. Group 3: Regulatory Information - A registration statement on Form S-1 was declared effective by the SEC on February 9, 2026, and the offering is being made only by means of a prospectus [4].

Group 1: Exelixis Overview - Exelixis has seen a stock increase of +30% over the last year, with Q4 sales expected to rise by 3% year over year to $584.68 million and Q4 EPS projected to increase by 40% to $0.77 compared to $0.55 in the prior year quarter [1][4] - The company received FDA acceptance for a New Drug Application for a combination therapy targeting metastatic colorectal cancer, marking its transition from a single-product biotech to a multi-asset oncology company [2][3] - Exelixis has consistently surpassed Zacks EPS Consensus for six consecutive quarters, with an average earnings surprise of 21.39% in its last four quarterly reports [4][5] Group 2: Gilead Sciences Overview - Gilead Sciences' stock has surged nearly +60% in the last year, with Q4 sales expected to be flat at $7.57 billion and quarterly EPS anticipated to dip 3% to $1.83 [1][10] - The company's HIV franchise, particularly Biktarvy, is highlighted as a primary long-term growth driver, contributing to a "wide moat" for the business [8] - Gilead's robust R&D pipeline, including oncology and virology programs, has been noted as the most extensive in the company's history, fueling investor sentiment [9] Group 3: Financial Projections - For fiscal 2025, Exelixis' annual EPS is expected to increase by 48% to $2.96, while Gilead Sciences' EPS is projected to grow by 76% to $8.14 per share [11] - Exelixis trades at an attractive 12X forward earnings multiple, compared to Gilead's 17X, which is still a slight discount to the Zacks Medical-Biomedical and Genetics Industry average [11] Group 4: Investment Ratings - Exelixis holds a Zacks Rank 1 (Strong Buy), while Gilead Sciences has a Zacks Rank 3 (Hold) ahead of their Q4 reports [12]

Core Viewpoint - RXO Inc (NYSE: RXO) is currently facing mixed market expectations, with various research firms adjusting their price targets and ratings, indicating potential downside from its current stock price [1][4]. Group 1: Price Targets and Ratings - Stephens has set a price target of $15 for RXO, suggesting a potential downside from the current stock price of $16 [1][4]. - The consensus rating for RXO from nineteen research firms is "Hold," with an average twelve-month target price of approximately $16.07, closely aligning with the current stock price [2][4]. - Citigroup has lowered its price target from $16 to $15 while maintaining a "neutral" rating, and Truist Financial has reduced its target from $20 to $18 but still recommends a "buy" [3]. Group 2: Stock Performance and Market Capitalization - RXO's stock price has fluctuated between $15.76 and $17.40 recently, with a one-year high of $22.17 and a low of $10.43 [3]. - The company's market capitalization is approximately $2.64 billion, with a trading volume of 2,392,948 shares on the NYSE [3].

Overview - Assets under management for spot crypto funds have decreased to $130 billion, marking the lowest level since March of the previous year, driven by significant net outflows and a decline in Bitcoin prices [1][2]. Market Dynamics - Bitcoin has fallen over 50% from its peak in October 2025, with approximately $7 billion in outflows, but most ETF investors remain committed for the long term [2][3]. - The selling pressure is primarily from original crypto investors who have been gradually trimming their positions rather than mass selling [3]. - Currently, about 40% of spot Bitcoin ETF holders are experiencing losses and require a 50% increase in Bitcoin prices to break even [4]. Investor Sentiment - There is a prevailing negative sentiment among investors, exacerbated by the rising price of gold, which has reached all-time highs, contrasting with the performance of cryptocurrencies [5][6]. - The lack of dip buying in ETFs suggests that many investors are hesitant, with flows often reflecting the price movements of Bitcoin or Ethereum rather than counter-trend buying [7][10]. ETF Flows and Strategies - Some financial advisors are viewing the current market as an opportunity, leading to inflows in certain products, while hedge funds and traders are contributing to outflows [8][9]. - The ETF market is characterized by two distinct investor groups: those seeking short-term gains and those focused on long-term investments [10][32]. - The recent performance of spot ETFs has not provided the same price support for Bitcoin as seen in previous cycles, indicating a shift in market dynamics [10][14]. Future Trends - There is growing interest in diversified index funds within the crypto space, similar to trends seen in traditional asset classes, as investors seek broader exposure [20][21]. - The retailization of institutional strategies is becoming a significant trend, with more retail investors gaining access to complex investment strategies previously reserved for high-net-worth individuals [34][36]. - The potential for more banks to issue crypto products could enhance market flows and investor participation [28][29].

Core Viewpoint - Edgewise Therapeutics is experiencing a positive market response following a bullish recommendation from analyst Yasmeen Rahimi of Piper Sandler, who has set a price target of $51 per share for the company's stock [2][3]. Company Overview - Edgewise Therapeutics' stock rose by 4% in a single day, outperforming the S&P 500 index, which only increased by 0.5% [2]. - The current stock price is $30.27, with a market capitalization of $3.1 billion [7]. Clinical Development - The company is advancing its leading cardiovascular drug candidate, EDG-7500, which targets hypertrophic cardiomyopathy (HCM) and is currently in a Phase 2 clinical trial [5][6]. - A readout from the clinical trial is expected in the second quarter of the calendar year, and the drug's novel functionality is anticipated to provide a competitive edge in the market [6]. Pipeline Potential - In addition to EDG-7500, Edgewise is developing Sevasemten, a treatment for muscular dystrophy, which is also well advanced in the development cycle [9]. - The analyst believes that several other pipeline programs have solid potential, indicating a robust future for the company's product offerings [9].

Company Overview - Cleveland-Cliffs Inc. is a leading iron ore mining company in the United States, specializing in producing iron ore pellets and serving as a major supplier to the North American steel industry [1] Financial Performance - CLF held its Q4 2025 earnings call, providing insights into its financial health and strategic plans, likely covering revenue, profit margins, and challenges faced during the quarter [3] - Currently, CLF's stock price is $12.16, marking a 17.48% decrease, with a trading range between $11.03 and $13.26 today [4] - Over the past year, the stock reached a high of $16.70 and a low of $5.63, reflecting significant volatility in its market performance [4] Market Position - Cleveland-Cliffs has a market capitalization of approximately $6.92 billion, indicating its size and market presence [5] - The company has a trading volume of 46.34 million shares on the NYSE, reflecting investor interest and market activity [5] Analyst Ratings - Citigroup maintained a Neutral rating for CLF, suggesting investors hold the stock, and raised its price target from $11 to $13, indicating cautious optimism about the company's future performance [2][6]

Core Insights - Amentum Holdings reported a revenue of $3.24 billion for the quarter ended December 2025, reflecting a 5.2% decline year-over-year and a revenue surprise of -2.98% compared to the Zacks Consensus Estimate of $3.34 billion. The EPS was $0.54, slightly up from $0.51 in the previous year, with an EPS surprise of +1.89% against the consensus estimate of $0.53 [1]. Financial Performance - Revenue from Global Engineering Solutions (GES) was $1.9 billion, falling short of the average estimate of $2.04 billion from three analysts [4]. - Revenue from Digital Solutions (DS) reached $1.34 billion, exceeding the average estimate of $1.27 billion from three analysts [4]. - Adjusted EBITDA for GES was reported at $160 million, slightly above the average estimate of $157.08 million from two analysts [4]. - Adjusted EBITDA for DS was $103 million, surpassing the average estimate of $99.45 million from two analysts [4]. Stock Performance - Amentum's shares have returned +11.6% over the past month, contrasting with a -0.2% change in the Zacks S&P 500 composite [3]. - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3].